(Q52654326)

5 May 2018

title

Low-dose IL-2 therapy - a complex scenario that remains to be further explored. (English)

1 reference

5 May 2018

2

Gabriela Riemekasten

1 reference

5 May 2018

Jens Y Humrich

1

1 reference

5 May 2018

language of work or name

English

0 references

publication date

11 May 2017

1 reference

5 May 2018

Nature Reviews Rheumatology

published in

1 reference

5 May 2018

volume

13

1 reference

5 May 2018

issue

6

1 reference

5 May 2018

page(s)

386

1 reference

5 May 2018

https://scigraph.springernature.com/pub.10.1038/nrrheum.2017.71

exact match

0 references

cites work

Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

The rise of IL-2 therapy - a picture beyond Treg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.71

31 March 2020

Identifiers

DOI

10.1038/NRRHEUM.2017.71

1 reference

5 May 2018

1 reference

5 May 2018